The outcome of aplastic anaemia associated with terbinafine therapy
  • Farhan Khalid
    Department of Internal Medicine, Monmouth Medical Center, New Jersey, USA
  • Sai Rakshith Gaddameedi
    Department of Internal Medicine, Monmouth Medical Center, New Jersey, USA
  • Ahmad Al-Alwan
    Department of Internal Medicine, Monmouth Medical Center, New Jersey, USA
  • Husam Bader
    Department of Internal Medicine, Monmouth Medical Center, New Jersey, USA
  • Doantrang Du
    Department of Internal Medicine, Monmouth Medical Center, New Jersey, USA
  • Trishala Meghal
    Department of Hematology/Oncology, Monmouth Medical Center, New Jersey, USA

Keywords

Aplastic anemia, terbinafine, fungi, thrombocytopenia, onychomycosis, pancytopenia

Abstract

Onychomycosis (OM), a widespread fungus that affects the toenails and/or fingernails, causes a large amount of morbidity and is very frequent in the general population. The best treatment is systemic antifungals. Terbinafine is a potent antifungal drug that works by targeting the keratin and lipids found in fungi. In the United States, the prevalence of this nail ailment ranges from 2% to 14%; it is 5.5% globally. Here, we describe a case of aplastic anaemia linked to oral terbinafine use. Clinicians should be aware of this rare adverse effect and early discontinuation of the treatment is required to prevent significant morbidity and mortality.

VIEW THE ENTIRE ARTICLE

References

  • Lipner SR, Scher RK. Onychomycosis: clinical overview and diagnosis. J Am Acad Dermatol 2019;80:835–851.
  • Bodman MA, Krishnamurthy K. Onychomycosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan.
  • Conjeevaram G, Vongthavaravat V, Sumner R, Koff RS. Terbinafine-induced hepatitis and pancytopenia. Dig Dis Sci 2001;46:1714–1716.
  • Gupta AK, Stec N, Summerbell RC, Shear NH, Piguet V, Tosti A, et al. Onychomycosis: a review. J Eur Acad Dermatol Venereol 2020;34:1972–1990.
  • Kovacs MJ, Alshammari S, Guenther L, Bourcier M. Neutropenia and pancytopenia associated with oral terbinafine. J Am Acad Dermatol 1994;31:806.
  • Gupta AK, Soori GS, Del Rosso JQ, Bartos PB, Shear NH. Severe neutropenia associated with oral terbinafine therapy. J Am Acad Dermatol 1998;38:765–767.
  • Scheinberg P. Aplastic anemia: therapeutic updates in immunosuppression and transplantation. Hematology Am Soc Hematol Educ Program 2012;2012:292–300.
  • Kantarcioglu B, Turkoz HK, Yilmaz G, Pepedil Tanrikulu F, Kaygusuz Atagunduz I, Adiguzel C, et al. Aplastic anemia associated with oral terbinafine: a case report and review of the literature. Turk J Haematol 2014;31:411–416.
  • Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–245.

    • Views: 332
    HTML downloads: 49
    PDF downloads: 227

    Published: 2023-12-20
    Issue: 2024: Vol 11 No 1 (view)

    How to cite:
    1.
    Khalid F, Gaddameedi SR, Al-Alwan A, Bader H, Du D, Meghal T. The outcome of aplastic anaemia associated with terbinafine therapy. EJCRIM 2023;11 doi:10.12890/2023_004142.

    Most read articles by the same author(s)